Trial Profile
Amyloid Deposition and Preexisting Vulnerable Carotid Plaque Features Predicting Cognitive Improvement After Surgery
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2024
Price :
$35
*
At a glance
- Drugs Flutemetamol-F-18 (Primary)
- Indications Cognition disorders; Inflammation
- Focus Diagnostic use
- 09 Jan 2024 Planned End Date changed from 10 Sep 2021 to 10 Sep 2024.
- 09 Jan 2024 Planned primary completion date changed from 10 Sep 2021 to 10 Sep 2024.
- 09 Jan 2024 Status changed from recruiting to active, no longer recruiting.